Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 2
Submit an article Journal homepage
1,283
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

Vernon F. SchabertIMS Health, Inc. Alexandria, VAUSACorrespondence[email protected]
,
Crystal WatsonAmgen, Inc. Thousand Oaks, CAUSA
,
Shravanthi R. GandraAmgen, Inc. Thousand Oaks, CAUSA
,
Seth GoodmanIMS Health, Inc. Alexandria, VAUSA
,
Kathleen M. FoxStrategic Healthcare Solutions LLC, Monkton, MDUSA
&
David J. HarrisonAmgen, Inc. Thousand Oaks, CAUSA
Pages 264-275 | Accepted 23 Nov 2011, Published online: 08 Dec 2011

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Augusto Afonso Guerra Júnior, Juliana Alvares Teodoro & Francisco de Assis Acurcio. (2019) Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert Review of Clinical Immunology 15:8, pages 879-887.
Read now
April W. Armstrong, Yang Zhao, Vivian Herrera, Yunfeng Li, Tim Bancroft, Michael Hull & Aylin Altan. (2017) Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan. Journal of Dermatological Treatment 28:7, pages 613-622.
Read now
Brian C. Sauer, Chia-Chen Teng, Tao He, Jianwei Leng, Chao-Chin Lu, Jessica A. Walsh, Neel Shah, David J. Harrison, Derek H. Tang & Grant W. Cannon. (2016) Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. Journal of Medical Economics 19:1, pages 34-43.
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Machaon Bonafede, George J Joseph, Neel Shah, Nicole Princic & David J Harrison. (2014) Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. ClinicoEconomics and Outcomes Research 6, pages 381-388.
Read now
Jeffrey R. Curtis, Vernon F. Schabert, Jason Yeaw, Jonathan R. Korn, Caroleen Quach, David J. Harrison, Huifeng Yun, George J. Joseph & David Collier. (2014) Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. Journal of Medical Economics 17:8, pages 555-566.
Read now
Machaon Bonafede, George J. Joseph, Nicole Princic & David J. Harrison. (2013) Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics 16:9, pages 1120-1128.
Read now
Mariano Ara & Esteban Daudén. (2013) Etanercept for the treatment of psoriasis. Expert Review of Dermatology 8:4, pages 357-372.
Read now
Maxine D. Fisher, Crystal Watson, Kathleen M. Fox, Yen-Wen Chen & Shravanthi R. Gandra. (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion 29:5, pages 561-568.
Read now
Marino Paroli. (2012) Clinical use of biologics in vasculitis syndromes. Biologics: Targets and Therapy 6, pages 371-378.
Read now
Chureen T. Carter, Arun K. Changolkar & R. Scott McKenzie. (2012) Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Journal of Medical Economics 15:2, pages 332-339.
Read now

Articles from other publishers (20)

Mahmoud Khatib A.A. Al-Ruweidi, Nada Khater, Haya Rashid Alkaabi, Maram Hasan, Mohammed Murtaza & Huseyin C. Yalcin. 2022. Immunology of the GI Tract - Recent Advances. Immunology of the GI Tract - Recent Advances.
Jiha Lee, Namrata Singh, Shelly L. Gray & Una E. Makris. (2022) Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More. ACR Open Rheumatology.
Crossref
Ana Duarte, Teumzghi Mebrahtu, Pedro Saramago Goncalves, Melissa Harden, Ruth Murphy, Stephen Palmer, Nerys Woolacott, Mark Rodgers & Claire Rothery. (2017) Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology Assessment 21:64, pages 1-244.
Crossref
Steven R. FeldmanYang ZhaoHuanxue ZhouVivian HerreraHaijun TianYunfeng Li. (2017) Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. Journal of Managed Care & Specialty Pharmacy 23:5, pages 583-589.
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov & Mark A. Ainsworth. (2016) Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases 22:8, pages 1999-2015.
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, George J. Joseph, David J. Harrison & Brian C. Sauer. (2016) Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy 33:8, pages 1347-1359.
Crossref
Zheng-Yi Zhou, Jenny Griffith, Ella Xiaoyan Du, Daniel Chin, Keith A. Betts & Arijit Ganguli. (2016) Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. Advances in Therapy 33:5, pages 807-823.
Crossref
Michael Guo, Hao Luo, Ali Samii & Mahyar Etminan. (2016) The Risk of Glioblastoma with TNF Inhibitors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:4, pages 449-454.
Crossref
Daryl PritchardAllison PetrillaShawn HallinanDonald H. TaylorJr.Jr., Vernon F. SchabertRobert W. Dubois. (2016) What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients. Journal of Managed Care & Specialty Pharmacy 22:2, pages 102-109.
Crossref
M. Cárdenas, S. de la Fuente, P. Font, M. C. Castro-Villegas, M. Romero-Gómez, D. Ruiz-Vílchez, J. Calvo-Gutiérez, A. Escudero-Contreras, M. A. Casado, J. R. Del Prado & E. Collantes-Estévez. (2015) Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. Rheumatology International 36:2, pages 231-241.
Crossref
Mark R. Trusheim & Ernst R. Berndt. (2015) The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. Drug Discovery Today 20:12, pages 1439-1450.
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Jacqueline Vanderpuye-Orgle, Yang Zhao, Jackie Lu, Anshu Shrestha, Alison Sexton, Seth Seabury & Mark Lebwohl. (2015) Evaluating the economic burden of psoriasis in the United States. Journal of the American Academy of Dermatology 72:6, pages 961-967.e5.
Crossref
Guillaume Moulis, Agnès Sommet, Maryse Lapeyre-Mestre & Jean-Louis Montastruc. (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology 53:10, pages 1864-1871.
Crossref
Ning Wu, Yuan-Chi (Daisy) Lee, Neel Shah & David J. Harrison. (2014) Cost of Biologics per Treated Patient across Immune-mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study. Clinical Therapeutics 36:8, pages 1231-1241.e3.
Crossref
Jason Yeaw, Crystal Watson, Kathleen M. Fox, Vernon F. Schabert, Seth Goodman & Shravanthi R. Gandra. (2014) Treatment Patterns Following Discontinuation of Adalimumab, Etanercept, and Infliximab in a US Managed Care Sample. Advances in Therapy 31:4, pages 410-425.
Crossref
Steven W. Blume, Kathleen M. Fox, George Joseph, Chien-Chia Chuang, Jessy Thomas & Shravanthi R. Gandra. (2013) Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting. Advances in Therapy 30:5, pages 517-527.
Crossref
Dragos Andrei Chiran, Gerhard Litscher, Michael Weber, Laura Marinela Ailioaie, Constantin Ailioaie & Daniela Litscher. (2013) Intravenous Laser Blood Irradiation Increases Efficacy of Etanercept in Selected Subtypes of Juvenile Idiopathic Arthritis: An Innovative Clinical Research Approach. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-9.
Crossref
Machaon M. K. Bonafede, Shravanthi R. Gandra, Crystal Watson, Nicole Princic & Kathleen M. Fox. (2012) Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis. Advances in Therapy 29:3, pages 234-248.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.